Valuation: GENinCode Plc

Market Cap 5.27M 6.96M 6.18M 5.78M 9.89M 670M 10.04M 69.85M 27.06M 341M 26.09M 25.55M 1.1B P/E 2026 *
-0.99x
P/E 2027 * -
Enterprise Value 4.97M 6.56M 5.83M 5.45M 9.33M 632M 9.47M 65.87M 25.52M 322M 24.61M 24.09M 1.04B EV / Sales 2026 *
1.55x
EV / Sales 2027 * -
Free-Float
59.68%
Yield 2026 *
-
Yield 2027 * -
1 week-20.00%
1 month-33.33%
3 months-24.73%
6 months-35.78%
Current year-70.83%
1 week 0.64
Extreme 0.636
0.9
1 month 0.64
Extreme 0.636
1.1
Current year 0.64
Extreme 0.636
2.5
1 year 0.64
Extreme 0.636
4.9
3 years 0.64
Extreme 0.636
10
5 years 0.64
Extreme 0.636
40
10 years 0.64
Extreme 0.636
48
Manager TitleAgeSince
Chief Operating Officer 51 2018-09-05
Chief Executive Officer 62 2018-09-05
Director of Finance/CFO 57 2020-10-31
Director TitleAgeSince
Chairman 62 2018-09-05
Director/Board Member 51 2018-09-05
Director/Board Member 65 2020-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
5/6/26 Free

Founder

30,428,453 4.0407%
5/6/26 Free

Chairman

1,267,852 0.1684%
5/6/26 Free

Chief Financial Officer

13,523,757 1.7959%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-20.00%-80.56%-92.82% 7M
-2.17%-6.57%-27.81%-0.17% 171B
+0.17%-3.20%-9.24%+10.31% 110B
-0.88%-0.16%-26.16%-0.11% 106B
-0.69%-3.57%-47.61%-12.45% 75.99B
+3.17%-0.80%-0.88%+72.13% 57.3B
-0.52%-2.44%-4.86%-31.12% 48.76B
+3.44%+7.90%+19.12%+59.15% 50.19B
-0.85%-0.82%-18.96%+18.41% 41.14B
-0.07%-1.71%+28.15%-7.58% 32.56B
Average +0.53%-3.31%-16.88%+1.57% 69.3B
Weighted average by Cap. +0.57%-2.07%-16.38%+9.01%

Financials

2026 *2027 *
Net sales 3.2M 4.22M 3.75M 3.51M 6M 406M 6.09M 42.36M 16.41M 207M 15.82M 15.49M 667M -
Net income -5.06M -6.68M -5.94M -5.55M -9.5M -643M -9.64M -67.06M -25.98M -328M -25.05M -24.53M -1.06B -
Net Debt -300K -396K -352K -329K -563K -38.11M -571K -3.98M -1.54M -19.42M -1.48M -1.45M -62.55M -
Logo GENinCode Plc
GENinCode Plc is a United Kingdom-based predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer. Its testing products include CARDIO inCode Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA Test. Its SITAB is an online Web portal, which provides health care practitioners with a systemized approach to request, record, process and report their clinical and genetic test results. Its CARDIO inCode Score is a genetic test for the evaluation of the coronary genetic load based on a polygenic risk score.
Employees
44
Date Price Change Volume
26-10-01 GBX 0.7000 0.00% 2,249,512
26-09-30 GBX 0.7000 0.00% 1,356,034
26-09-29 GBX 0.7000 -20.00% 22,954,144
26-09-28 GBX 0.8750 0.00% 94,424
26-09-25 GBX 0.8750 0.00% 718,083
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.007000GBP
Average target price
0.0750GBP
Spread / Average Target
+971.43%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GENI Stock